Interview with the Innovators

Interview with the Innovators

Ovarian Suppression: What Are Some of the Important Questions That Women Ask?
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, examine fertility issues associated with ovarian function suppression and the psychosocial impact it has on young breast cancer patients.

Setting Patients’ Expectations When They Are Prescribed Combination Therapy for Premenopausal Breast Cancer
This Interview with the Innovator video features two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, reviewing combination therapy with ovarian function suppression and its effects in breast cancer patients, including the importance of setting up-front expectations of treatment.

Oncology Nurse Navigators Discuss Their Best Practices to Encourage Premenopausal Breast Cancer Patients to Adhere to Their Therapy
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, highlight the challenges with ovarian function suppression side effects patients face and explore tactics to encourage adherence to treatment.

Sexual Health Dysfunction Associated With Ovarian Function Suppression: How Do I Start the Discussion With My Premenopausal Breast Cancer Patient?
Gain insights from Emily Beard, RN, BSN, OCN, CBCN, breast oncology nurse navigator, in this Interview with the Innovator video on communication techniques to discuss sensitive topics with breast cancer patients including sexual health dysfunction associated with ovarian function suppression.

Ovarian Function Suppression Side Effects to Monitor & Report to HCP
In this Interview with the Innovator video, Melissa Simon, BSN, RN, OCN, ONN-CG, and Emily Beard, RN, BSN, OCN, CBCN, discuss common and expected side effects with ovarian function suppression as well as adverse side effects to monitor and report to a healthcare provider.

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The American Cancer Society estimates over 20,000 new CLL cases and over 4000 attributed deaths in 2022.

Insights into the Prostate Cancer Imaging Landscape
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.

Results from the OSPREY Trial in Pre-Prostatectomy Patients
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.

PYLARIFY Imaging in High-Risk Prostate Cancer
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.

Overview of the Molecular Characteristics of PYLARIFY
Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®.

Page 3 of 12

Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country